Dr. Stephen Ansell discusses the emerging role of immunotherapy in the management of patients with Hodgkin lymphoma.
This activity is intended for hematologists, oncologists, pathologists, and other healthcare professionals who treat patients with Hodgkins lymphoma.
The goal of this activity is to discuss the latest understanding of the role of the immune system in the development of Hodgkin lymphoma as well as strategies for harnessing the immune
Approximate Time to Complete: 30 minutes
Course Available Beginning: Aug. 14, 2016
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the current challenges in the treatment and management of patients with relapsed/refractory HL
- Have increased knowledge regarding the role of immunotherapy as a potential approach for the treatment of patients with relapsed/refractory HL
- Have increased knowledge regarding the efficacy and safety of cancer immunotherapies being studied in clinical trials for the treatment and management of patients with relapsed/refractory HL